X4 Pharmaceuticals, Inc.

As of August 8, 2025, X4 Pharmaceuticals, Inc. has shifted from an attractive to a risky valuation grade due to overvaluation and poor financial metrics, including a Price to Book Value of 1.08 and a ROCE of -878.57%, alongside significant underperformance against the S&P 500 with a year-to-date return of -85.28%.

As of May 1, 2025, X4 Pharmaceuticals, Inc. is considered undervalued with a price-to-book value of 1.08 and an EV to sales ratio of 0.47, suggesting a potential buying opportunity despite recent negative returns and challenges.

As of June 11, 2025, X4 Pharmaceuticals, Inc. has shifted to a bearish trend, supported by negative signals from daily moving averages, monthly RSI, Bollinger Bands, KST, and Dow Theory, indicating significant downward momentum.

As of March 2022, the management team of X4 Pharmaceuticals, Inc. includes Independent Chairman Mr. Michael Wyzga, CEO Dr. Paula Ragan, Directors Ms. Alison Lawton, Dr. Rene Russo, Independent Directors Mr. William Aliski, Dr. Gary Bridger, and Mr. David McGirr. They oversee the company's strategic direction and operations.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases, including primary immunodeficiencies and cancer. As of March 2025, it has a market cap of $15.86 million and reported net sales of $29 million with no net profit.

As of Jun 18, X4 Pharmaceuticals, Inc. has a market capitalization of 15.86 million and reported net sales of 31.36 million and net profit of 14.59 million over the latest four quarters.